Multiple “Omics” data-based biomarker screening for hepatocellular carcinoma diagnosis

Abstract excerpt

The huge prognostic difference between early and late stage hepatocellular carcinoma (HCC) is a challenging diagnostic problem. Alpha-fetoprotein is the mostly widely used biomarker for HCC used in the clinic, however it's sensitivity and specificity of is not optimal. The development and application of multiple biotechnologies, including next generation sequencing, multiple "omics" data, that include genomics,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Hepatocellular Carcinoma Treatment and Prognosis
• Share to Liver Disease Diagnosis and Treatment
• Share to Pancreatic and Hepatic Oncology Research